Evidence map›Paper›PMID 41519994›Full record

ArticleNature communications2026

Transcriptomic signature-guided depletion of intermediate alveolar epithelial cells ameliorates pulmonary fibrosis in mice.

Fei Peng, Chun-Sun Jiang, Zhen Zheng, Shahram Aliyari, Dan Shan, Aaryan Sabharwal, Qinyan Yin, Shigeki Saito, Chao He, Ivan O Rosas and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Murine models of pulmonary fibrosis: mechanisms, limitations and translational insights.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Fei Peng *Section of Pulmonary Diseases, Critical Care and Environmental Medicine, John W. Deming Department of Medicine, Tulane University, New Orleans, LA, USA.
Chun-Sun Jiang *Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Zhen Zheng *Section of Pulmonary Diseases, Critical Care and Environmental Medicine, John W. Deming Department of Medicine, Tulane University, New Orleans, LA, USA.
Shahram AliyariInstitute of Pathology Heidelberg, University Hospital Heidelberg, Heidelberg University, Heidelberg, Germany.
Dan ShanSection of Pulmonary Diseases, Critical Care and Environmental Medicine, John W. Deming Department of Medicine, Tulane University, New Orleans, LA, USA.
Aaryan SabharwalSection of Pulmonary Diseases, Critical Care and Environmental Medicine, John W. Deming Department of Medicine, Tulane University, New Orleans, LA, USA.
Qinyan YinSection of Pulmonary Diseases, Critical Care and Environmental Medicine, John W. Deming Department of Medicine, Tulane University, New Orleans, LA, USA.
Shigeki SaitoSection of Pulmonary Diseases, Critical Care and Environmental Medicine, John W. Deming Department of Medicine, Tulane University, New Orleans, LA, USA.
Chao HeSection of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Ivan O RosasSection of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Joseph A LaskySection of Pulmonary Diseases, Critical Care and Environmental Medicine, John W. Deming Department of Medicine, Tulane University, New Orleans, LA, USA.
Victor J ThannickalSection of Pulmonary Diseases, Critical Care and Environmental Medicine, John W. Deming Department of Medicine, Tulane University, New Orleans, LA, USA.ORCID http://orcid.org/0000-0003-4266-8677
Yong ZhouSection of Pulmonary Diseases, Critical Care and Environmental Medicine, John W. Deming Department of Medicine, Tulane University, New Orleans, LA, USA. yzhou40@tulane.edu.ORCID http://orcid.org/0000-0003-3131-1912

Funding

Mechano-niche in Lung Repair after InjuryR01HL156973 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZHOU, YONG · 2021 to 2024
$2.4M
Targeting Matrix Stiffness in Lung Fibrosis Associated with AgingR01HL139584 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZHOU, YONG · 2018 to 2024
$2.2M
The Desmosome-Keratin Intermediate Filament Network in Lung Epithelial Injury, Repair and RegenerationR01HL174994 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI YONG ZHOU · 2025 to 2026
$1.4M
NHLBI NIH HHS R01 HL139584NHLBI NIH HHS R01 HL156973NHLBI NIH HHS R01 HL174994U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL139584U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL156973U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL174994
6 · The paper itself

Abstract

Single-cell RNA sequencing (scRNA-seq) has identified intermediate epithelial states in pulmonary fibrosis, including KRT5-/KRT17+ aberrant basaloid cells in humans and Krt8+ alveolar differentiation intermediates (ADIs) in mice. Their functional contributions to fibrogenesis, however, remain unclear. Here, we introduce an RNA-sensing-dependent protein translation technology that enables selective targeting of Krt8+ ADI cells in vitro and in vivo. Transcriptomic analysis revealed Small Proline-Rich Protein 1 A (SPRR1A) mRNA as a shared marker of murine Krt8+ ADIs and human KRT5-/KRT17+ basaloid cells, distinguishing them from other lung cell populations. Using programmable RNA sensors, we demonstrated selective EGFP-labeling of Krt8+ ADI cells in vivo, which faithfully recapitulated their transcriptomic and phenotypic features. To test function, we developed an RNA-sensing-driven diphtheria toxin receptor (DTR) system for conditional ablation of Sprr1a+ cells. Targeted depletion markedly reduced fibrosis in bleomycin-injured mice, establishing transitional epithelial cells as pathogenic drivers and highlighting their potential as therapeutic targets in pulmonary fibrosis.

Indexed as

Alveolar Epithelial CellsPulmonary FibrosisTranscriptomeAnimalsBleomycinCell DifferentiationCornified Envelope Proline-Rich ProteinsDisease Models, AnimalFemaleGene Expression ProfilingHumansLungMaleMiceMice, Inbred C57BLPulmonary AlveoliBleomycinCornified Envelope Proline-Rich Proteins

Identifiers

PMID41519994
PMCPMC12905394

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.